Drug Trial Radar · NCT06136598
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Jan 30, 2024
Primary completion
Mar 9, 2026
Study completion Mar 9, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Orion Corporation, Orion Pharma
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the safety and tolerability of opevesostat in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the pharmacokinetic profile of opevesostat. There are no formal hypotheses to be tested in this study.
Conditions
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
Interventions
OpevesostatDrug
Tablets to be taken orally.
DexamethasoneDrug
Tablets to be taken orally
FludrocortisoneDrug
Tablets to be taken orally.
HydrocortisoneDrug
Tablet to be taken orally as a rescue medication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 20 months
- Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 20 months
- Maximum Plasma Concentration (Cmax) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
- Time to Maximum Plasma Concentration (Tmax) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
- Area Under the Curve from Time 0 to 12 hours postdose (AUC0-12) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
- Apparent Volume of Distribution (Vz/F) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
- Oral Clearance (CL/F) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
- Half-Life (t1/2) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital-Urology ( Site 0001)
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003)
Guangzhou, Guangdong, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 0002)
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.